- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
- Latest weekly return ranks in the strongest part of its sector group.
ABL
GER
Week ended 24 Jul 2026
Weekly Investor Report
Abbott Laboratories · Healthcare · Medical Devices
Latest close
91.08 EUR
3.6%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 4.9% above the Trend Line and sits at 47.3% of its 52-week range. The latest completed week returned 3.6%, after a 10.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is expensive relative to peers. The latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal.
Setup score
43
out of 100
Latest Close
91.08 EUR
24 Jul 2026
1W Return
3.6%
latest completed week
4W Return
10.4%
short-term follow-through
12W Return
17.6%
quarterly tape
Trend Breadth
0.0%
0 of 52 weeks active
Volume Ratio
0.7x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is weak, so confirmation is not yet broad enough.
- The share remains more than 20% below its 52-week high.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
3.6%
Latest completed week; four-week move 10.4%.
Indicator stack
0/90
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Recent
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
51/100
20 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 4.9% above the Trend Line and sits at 47.3% of its 52-week range. The latest completed week returned 3.6%, after a 10.4% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1012-week average 0.03
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.10Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 10.4% over four weeks, 17.6% over 12 weeks, and -13.6% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.03Latest activity-pressure read.
Pressure change271.0%Four-week change in activity pressure.
Leadership-8.84Latest relative-leadership reading.
RS change50.0%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is expensive relative to peers.
Factor week 26 Jul 2026
Financial statements through 31 Dec 2025
Field coverage 88%
Model confidence 88%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength13/100Blend of value, momentum, and quality. Underlying universe rank 88; rank 1 is best.
Value19/100Relative valuation strength. Underlying universe rank 82; rank 1 is best.
Quality69/100Profitability and accounting quality. Underlying universe rank 32; rank 1 is best.
Momentum23/100Medium-term price momentum. Underlying universe rank 78; rank 1 is best.
Growth46/100Revenue and earnings growth. Underlying universe rank 55; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework36/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 24.3x Price divided by trailing earnings.
- Price / sales
- 3.6x Market value relative to trailing revenue.
- EV / EBITDA
- 15.4x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 4.0% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 56.4% Gross profit retained from each unit of revenue.
- Operating margin
- 18.2% Operating profit retained from revenue.
- Free-cash-flow margin
- 16.7% Free cash flow generated from revenue.
- Return on invested capital
- 7.6% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 2.4% Cash dividends relative to market value.
- Buyback yield
- 0.3% Net share repurchases relative to market value.
- Shareholder yield
- 2.7% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.3x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment51/100
Weighted news tone is neutral across 20 relevant articles.
1 positive · 19 neutral · 0 negativePatient CapitalRecent
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-20.4%Distance below the 52-week high.
13-week volatility4.7%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher13 of 2613 weeks finished lower.
Best week+9.0%Week of 26 Jun.
Worst week-6.2%Week of 8 May.
Latest week+3.6%Week of 24 Jul.
Shape of recent returns
Strong gains3
Modest gains10
Flat weeks0
Modest losses9
Sharp losses4
Recent vol4.7%13-week weekly-return volatility.
Base vol3.6%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew2.5% / -2.7%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank7 / 78
Group average1.5%
Trend breadth38.5%
Trend38.5%active weekly trend signals
MD64.1%positive activity pressure
RS43.6%positive relative leadership
Four-week leaders
IndustryDE Medical Devices
4-week rank4 / 12
Group average3.0%
Trend breadth33.3%
Trend33.3%active weekly trend signals
MD66.7%positive activity pressure
RS33.3%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape35/100
Trend, activity pressure, participation, and risk combine to a 35/100 tape read.
Indicator analysis15/100Latest 12-week confirmation: trend 0/12, activity pressure 3/12, relative leadership 0/12.
Activity pressure 0.10; No reversal markers Factors30/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 36 SVQF36/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 239.0 of 373 Patient CapitalRecentActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks Sentiment51/100Weighted news tone is neutral across 20 relevant articles.
Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 91.08 EUR | 3.6% | 86.85 EUR | 99.42 EUR | 1.03 | -8.84 | 4.0K | Off |
| 17 Jul 2026 | 87.92 EUR | 7.9% | 87.29 EUR | 99.45 EUR | 0.92 | -11.36 | 13.6K | Off |
| 10 Jul 2026 | 81.46 EUR | -1.5% | 87.86 EUR | 99.50 EUR | 0.35 | -18.91 | 4.6K | Off |
| 3 Jul 2026 | 82.73 EUR | 0.3% | 88.64 EUR | 99.56 EUR | -0.12 | -20.41 | 5.9K | Off |
| 26 Jun 2026 | 82.47 EUR | 9.0% | 89.44 EUR | 99.62 EUR | -0.60 | -17.67 | 4.8K | Off |
| 19 Jun 2026 | 75.69 EUR | 0.1% | 90.35 EUR | 99.69 EUR | -1.02 | -25.85 | 419 | Off |
| 12 Jun 2026 | 75.63 EUR | -4.8% | 91.46 EUR | 99.80 EUR | -1.07 | -25.49 | 1.5K | Off |
| 5 Jun 2026 | 79.48 EUR | 8.2% | 92.61 EUR | 99.89 EUR | -1.04 | -22.75 | 870 | Off |
| 29 May 2026 | 73.48 EUR | -2.5% | 93.55 EUR | 99.95 EUR | -0.99 | -30.06 | 9.5K | Off |
| 22 May 2026 | 75.38 EUR | 3.8% | 94.63 EUR | 100.1 EUR | -1.00 | -28.23 | 8.0K | Off |
| 15 May 2026 | 72.64 EUR | 0.1% | 95.72 EUR | 100.2 EUR | -1.02 | -28.70 | 11.7K | Off |
| 8 May 2026 | 72.60 EUR | -6.2% | 96.91 EUR | 100.3 EUR | -1.01 | -30.47 | 8.7K | Off |
| 1 May 2026 | 77.42 EUR | -0.9% | 98.26 EUR | 100.4 EUR | -1.00 | -26.37 | 4.4K | Off |
| 24 Apr 2026 | 78.12 EUR | -4.6% | 99.42 EUR | 100.5 EUR | -0.99 | -25.77 | 7.5K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.